Sarepta TherapeuticsSRPT
SRPT
About: Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Employees: 1,372
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
26% more call options, than puts
Call options by funds: $102M | Put options by funds: $81.3M
5% less repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 149
3.56% less ownership
Funds ownership: 92.04% [Q4 2024] → 88.48% (-3.56%) [Q1 2025]
7% less funds holding
Funds holding: 458 [Q4 2024] → 424 (-34) [Q1 2025]
29% less first-time investments, than exits
New positions opened: 72 | Existing positions closed: 101
48% less capital invested
Capital invested by funds: $10.7B [Q4 2024] → $5.52B (-$5.16B) [Q1 2025]
55% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 5 (-6) [Q1 2025]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
11%
upside
Avg. target
$87
139%
upside
High target
$125
245%
upside
14 analyst ratings
10 positive
71%
4 neutral
29%
0 negative
0%
Scotiabank Louise Chen | 121%upside $80 | Sector Outperform Upgraded | 6 Jun 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 11%upside $40 | Neutral Reiterated | 22 May 2025 |
JP Morgan Anupam Rama | 132%upside $84 | Overweight Maintained | 20 May 2025 |
Wells Fargo Yanan Zhu | 176%upside $100 | Overweight Maintained | 8 May 2025 |
RBC Capital Brian Abrahams | 60%upside $58 | Sector Perform Maintained | 7 May 2025 |
Financial journalist opinion
Based on 8 articles about SRPT published over the past 30 days
Negative
Reuters
10 hours ago
Sarepta reports second case of liver failure death after its gene therapy treatment
Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy for a rare form of muscular dystrophy.
Neutral
Business Wire
12 hours ago
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of.
Positive
Zacks Investment Research
1 week ago
Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Neutral
Zacks Investment Research
1 week ago
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
Neutral
Business Wire
1 week ago
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration. “This is one of the first programs to receive platform technology designation.
Neutral
Business Wire
3 weeks ago
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303. EN.
Neutral
Business Wire
4 weeks ago
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study of ELEVIDYS (delandistrogene moxeparvovec-rokl) for the treatment of Duchenne muscular dystrophy. Treatment with ELEVIDYS in the ENDEAVOR participants in cohort 6 who were 2 years old at the time of treatment (n=6), demonstrated mean expression of 93.
Neutral
Business Wire
4 weeks ago
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data from Part 2 of the EMBARK study that continue to support the clinical benefits of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. These data are among other ELEVIDYS data from Sarepta's portfolio presented during the 28th annual meeting of the American Society.
Positive
MarketBeat
1 month ago
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound.
Neutral
Business Wire
1 month ago
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals ages 3- to less than 8-years-old, who do not have any deletions in exo.
Charts implemented using Lightweight Charts™